Dr. Jonathan Rothberg, Ph.D. invented the technology and initiated projects to sequence the first human genome (James Watson), the Neanderthal Genome, and crack the disappearance of the honey bees (CCD). Jonathan earned a B.S. in chemical engineering with an option in Biomedical engineering from Carnegie Mellon University and an M.S., M.Phil, and Ph.D. in biology from Yale University. Dr. Rothberg is the founder of 454 Life Sciences, Clarifi Corporation, CuraGen Corporation, The Rothberg Institute for Childhood Diseases, and the co-founder and Chairman of RainDance Technologies. Dr. Rothberg was named an Ernst and Young Entrepreneur of the Year and is the receipt of The Wall Street Journal?s Gold Medal for Innovation for his invention of 454 sequencing, and The Irvington Institute?s Corporate Leadership Award in Science. Dr. Rothberg is a member of the National Academy of Engineering, the Connecticut Academy of Science and Engineering, and serves on the board of trustees of Carnegie Mellon University.
Bill Ericson leads investments in life sciences and software for Mohr Davidow Ventures. He works closely with a cross-discipline team of leading scientists, researchers and entrepreneurs applying technology solutions to life sciences and health care in non-traditional ways. Bill joined MDV after spending 10 years working with and investing in entrepreneurs and early stage companies. During that time, he served as a board member of a number of life sciences and software companies, both public and private. Bill was a member of the founding team of Rosetta Inpharmatics and served on the Board of Directors until its acquisition by Merck in 2001. Bill serves on the Board of Northwestern University School of Law and is a member of the Personalized Medicine Coalition. Bill received his B.S.F.S. from Georgetown University of Foreign Service and J.D. from Northwestern University School of Law.
Michael Hunkapiller joined Alloy in 2004 after 21 years at Applied Biosystems (NYSE: ABI), which he helped grow from startup to almost $2 billion in annual revenues supplying instrument and reagent systems for life science research. At ABI, he held several positions, most recently as President and General Manager. He was also a founder of ABI's sister company Celera Genomics (NYSE: CRA) and Senior Vice President of Applera Corporation (their parent company). Prior to joining ABI, Mike was a senior research fellow in the Division of Biology at the California Institute of Technology. He received a B.S. in Chemistry from Oklahoma Baptist University in 1970 and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech in 1974. He has authored more than 100 scientific publications, is an inventor on more than two dozen patents, and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research, including the development of the automated DNA sequencing systems used to sequence the human genome. Mike is currently on the board of directors of Codon Devices, Fluidigm, and Pacific Biosciences.
Board Observer - Jeff Samberg is the Managing Member of Acadia Woods Partners, LLC, a New York based investment partnership that focuses primarily on early stage technology companies. Jeff lived in the San Francisco Bay Area for 15 years where he held a number of high-tech management roles, including Vice President of Corporate Strategy for PeopleSoft Inc., Vice President of Business Development for Wily Technology, and Entrepreneur in Residence for Greylock Partners. Jeff received his MBA from Stanford University's Graduate School of Business and his B.A. with high honors in Economics from Princeton University.
Sue Siegel is a Partner with Mohr Davidow Ventures. Prior to joining MDV Sue was President and Director of Affymetrix, Inc., a company that pioneered GeneChip(R) technology, propelling the expansion of the genomics field and the opportunity for personalized medicine. Formerly, Siegel was at Amersham International (now GE Healthcare) where her last role was President of the Hoefer-Pharmacia Biotech business. Previously, she built her experience in biotechnology and healthcare at E. I. DuPont & Co., Eastman Kodak Co., and Bio-Rad Laboratories. Siegel is also a member of the board of directors of Pacific Biosciences. She is a member of the Presidents' Circle of the National Academies, serves as an advisor to the Institute of Medicine, and is a board member of The Tech Museum of Innovation, Silicon Valley. She is a member of the Advisory Council of The J. David Gladstone Institutes in San Francisco, a world leading biomedical research organization.
David A. Weitz, Ph.D. is the Mallinckrodt Professor of Physics and of Applied Physics, Harvard University, from 1999 to the present, and the Director of the Harvard Materials Research Science and Engineering Center, from 2001 to the present. Honors and Awards include Bayer Distinguished Lecture, Dept. of Chemical Engineering, U. Pittsburgh; Sir Eric Rideal Lecture, Faraday Discussions 123, Edinburgh, Scotland, Fellow of the American Physical Society.
